• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study
【24h】

The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study

机译：丙型肝炎病毒直接作用抗病毒药对患者报告结果的影响：荷兰前瞻性队列研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionPegylated interferon-based therapy for hepatitis C virus (HCV) negatively impacts nutritional state and patient-reported outcomes (PROs) such as health-related quality of life (HRQL). Clinical trials with direct-acting antivirals (DAAs) report significant PRO improvement but real-world data are still scarce. MethodsProspective cohort study recruiting HCV patients treated with DAAs in 2015–2016. Data at baseline, end of treatment (EOT) and 12?weeks thereafter (FU12) included: patient-reported medication adherence; SF-36; Karnofsky Performance Status; paid labour productivity; physical exercise level; nutritional state [by body mass index (BMI) and Jamar hand grip strength (HGS)] and Beliefs about Medicines Questionnaire. Potential factors predicting these PROs were evaluated with multiple regression analysis. ResultsA total of 68 patients were enrolled: 85% male, median age 57?years, 80% genotype 1, 40% cirrhotics, 46% haemophilia. Both cure rate and patient-reported adherence were 97%. SF-36 Physical Component Summary did not change (43.2?±?11.9, 44.9?±?10.3 and 44.7?±?10.9 at baseline, EOT and FU12, p =?0.71). In contrast, SF-36 mental component summary (MCS) decreased transiently during therapy (49.2?±?11.9, 44.6?±?10.3 and 49.9?±?12.6 at baseline, EOT and FU12, p 12, p =?0.56) did not change. ConclusionOur study reveals concomitant ribavirin as the only independent predictor of transient decrease in SF-36 mental HRQL during DAA therapy. In contrast to interferon-based therapy, DAAs do not affect BMI or Jamar HGS.
机译：简介基于聚乙二醇干扰素的丙型肝炎病毒（HCV）治疗会对营养状况和患者报告的结局（PRO）（例如与健康相关的生活质量（HRQL））产生负面影响。使用直接作用抗病毒药（DAA）的临床试验报告PRO有了显着改善，但实际数据仍然很少。方法：前瞻性队列研究招募了2015–2016年接受DAA治疗的HCV患者。基线，治疗结束（EOT）以及此后12周（FU 12 ）的数据包括：患者报告的用药依从性; SF-36;卡诺夫斯基绩效状况;有偿劳动生产率;体育锻炼水平;营养状态[通过体重指数（BMI）和Jamar手握力（HGS）]和有关药物问卷的信念。通过多元回归分析评估了预测这些PRO的潜在因素。结果共纳入68例患者：男性85％，中位年龄57岁，基因型1为80％，肝硬化患者为40％，血友病患者为46％。治愈率和患者报告的依从性均为97％。 SF-36物理成分摘要未发生变化（基线时为43.2？±？11.9、44.9？±？10.3和44.7？±？10.9，EOT和FU 12 ，p =？0.71）。相比之下，治疗期间SF-36精神成分摘要（MCS）短暂下降（基线时为49.2±11.9、44.6±10.3和49.9±12.6，EOT和FU 12 ，p 12 ，p =？0.56）没有变化。结论我们的研究表明，伴随病毒唑是DAA治疗期间SF-36精神HRQL短暂降低的唯一独立预测因子。与基于干扰素的治疗相反，DAA不会影响BMI或Jamar HGS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号